suppressing proinflammatory cytokine production, including IL-1β, TNF-α, and NO
Front Neuroanat. 2024 Dec 16;18:1511951
GIBH-130 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Mice
PTZ kindling model and KA model
Oral
0.25 mg/kg
Once daily until the end of the behavior test
Inhibiting the release of inflammatory factors by activated microglial cells, it was found that when the inflammatory response mediated by activated microglial cells was inhibited, the mortality of mice with increased intestinal K. pneumoniae abundance during generalized tonic-clonic seizures was significantly increased.
Cell Death Discov. 2021 Jul 7;7(1):175
Male C57BL/6 mice
6-hydroxydopamine (6-OHDA) unilateral striatal injection-induced Parkinson's disease model
Oral gavage
1 mg/kg
Once daily for 7 days
Alleviated motor impairment, reduced dopaminergic neuron death, decreased microglia density, restored its morphology, and prevented the increase in pro-inflammatory cytokine levels
Front Neuroanat. 2024 Dec 16;18:1511951
CD1 mice
Neonatal hypoxic-ischemic brain injury model
Intraperitoneally (pre-treatment) or subcutaneously (post-treatment)
1 mg/kg
Single dose (pre-treatment or post-treatment at 1, 3, and 6 h) or daily administration for 21 days
To evaluate the protective effect of AD-16 on neonatal hypoxic-ischemic brain injury. Results showed that AD-16 significantly reduced brain infarct volume, improved neurobehavioral outcomes, and reduced mortality rate.
搜索
